Evidence map›Paper›PMID 37415592›Full record

ArticleClinical case reports2023

Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test.

Shun Ishido, Nobuharu Tamaki, Kento Inada, Jun Itakura, Yuka Takahashi, Naoki Uchihara, Keito Suzuki, Yuki Tanaka, Haruka Miyamoto, Michiko Yamada and 11 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Shun IshidoDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.ORCID https://orcid.org/0000-0002-7036-5633
Nobuharu TamakiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Kento InadaDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Jun ItakuraDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Yuka TakahashiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Naoki UchiharaDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Keito SuzukiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Yuki TanakaDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Haruka MiyamotoDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Michiko YamadaDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Hiroaki MatsumotoDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Tsubasa NobusawaDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Taisei KeitokuDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Kenta TakauraDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Shohei TanakaDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Chiaki MaeyashikiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Yutaka YasuiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Kaoru TsuchiyaDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Hiroyuki NakanishiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Masayuki KurosakiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Namiki IzumiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Musashino Red Cross Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The liquid CGP was useful for detecting FGFR2 fusion and the patient experienced typical side effects (nail disorders, hyperphosphatemia, and taste disorders) of pemigatinib that required treatment.

Indexed as

comprehensive genomic profilingfibroblast growth factor receptor 2intrahepatic cholangiocarcinomapemigatinib

Identifiers

PMID37415592
PMCPMC10320371
OpenAlexW4383226517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.